US pharma major AbbVie saw its shares drop 4.5% to $218.04 by close of trading on Friday, despite reporting financial results for the third quarter ended September 30, 2025, that beat expectation.
The top 20 global biopharmaceutical companies saw their combined market capitalization rise 4% in the third quarter of 2025 ...
US biotech 4D Molecular Therapeutics (Nasdaq: FDMT) has granted Japan’s Otsuka Pharmaceutical (TYO: 4578) exclusive rights to ...
German family-owned pharma major Boehringer Ingelheim has licensed a pre-clinical program from Japan’s Kyowa Kirin to develop ...
US anti-virals giant Gilead Sciences late yesterday announced its third quarter 2025 results of operations, reporting total ...
Merck & Co (NYSE: MRK) posted third-quarter 2025 revenue of $17.3 billion, up 4% year over year, while adjusted earnings rose ...
The US Health Resources and Services Administration (HRSA) has approved nine drugs for a pilot testing a new rebate model ...
King Faisal Specialist Hospital & Research Centre (KFSHRC) has begun in-house manufacturing and clinical use of CAR-T cell ...
Swiss pharma major Roche (ROG: SIX) has entered a global exclusive licensing agreement with China’s Qyuns Therapeutics for ...
Swiss pharma giant Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic ...
The European Medicines Agency’s Pharmacovigilance Risk Committee (PRAC) has agreed on a direct healthcare professional communication (DHPC) to remind healthcare professionals that extreme caution ...
US biotech Biogen (Nasdaq: BIIB) reported third-quarter 2025 revenue of $2.5 billion, up 3%, with GAAP diluted EPS of $3.17, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback